Biotechs with the size of Xoma are valued at least 5x times higher. Weak markets and reverse split fears caused the drop from $12 to current price.
Xoma is incredible cheap with
- $60 mln reveneus in 2010 - 225 employees - manufacturing capabilities - unique antibody technology licensed to over 60 companies - major collaborations with big pharmas Merck, Novartis, Takeda - biodenfense drug selling to govt, $100 mln contracts so far
Xoma's lead drug Xoma 052 for multiple indications is in several phase II trials and got orphan drug designation for auto-immunce disease behcet.
Xoma 052, a unique IL-1 inhibitor with $20 bln sales potential for treatment of
- diabetes type 1 - diabetes type 2 - cardiovascular diseases - gout - behcet disease
Do your DD about Xoma. There's is no other small biotech out there with such a promising pipeline and antibody technology.
exactly and xomas net worth is in the billions despite the market cap ..their antibodies are worth billions ..right now ..not in the future ...now ...xoma is not forsale ..unless the price hits over 3 billion ..partnerships prices are only going up as good news arrives ..
The patents cover methods of treatment for Type 1 diabetes and certain cancers, including multiple myeloma, using XOMA 052 or other IL-1 beta antibodies with similar binding characteristics to XOMA 052.